{
    "ticker": "PRG",
    "name": "Progenity, Inc.",
    "description": "Progenity, Inc. is a biotechnology company focused on advancing molecular testing and improving patient outcomes through innovative genetic and diagnostic solutions. Founded in 2010 and headquartered in San Diego, California, Progenity specializes in non-invasive prenatal testing (NIPT) and other genetic testing services that empower patients and healthcare providers with critical information. The company's flagship product, the 'Inherit' test, is designed to assess the risk of genetic disorders in pregnancies, providing families with essential insights to make informed decisions. Additionally, Progenity offers a range of other genetic tests for various conditions, including gastrointestinal and hereditary cancers. With a commitment to research and development, Progenity is dedicated to expanding its portfolio of tests and leveraging advanced technologies such as next-generation sequencing (NGS) to enhance its offerings. The company aims to transform the landscape of genetic testing, ensuring that healthcare providers have access to the most accurate and actionable data. Progenity is also focused on building partnerships with healthcare systems and providers to improve patient care and accessibility to advanced diagnostic solutions. By prioritizing innovation and patient-centric approaches, Progenity strives to become a leader in the rapidly evolving field of molecular diagnostics.",
    "industry": [
        "Biotechnology",
        "Healthcare"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2010",
    "website": "https://www.progenity.com",
    "ceo": "Harry Stylli",
    "social_media": {
        "twitter": "https://twitter.com/Progenity",
        "linkedin": "https://www.linkedin.com/company/progenity/"
    },
    "investor_relations": "https://investors.progenity.com",
    "key_executives": [
        {
            "name": "Harry Stylli",
            "position": "CEO"
        },
        {
            "name": "Mark R. McKenna",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Genetic Testing",
            "products": [
                "Inherit",
                "Gastrointestinal Tests",
                "Hereditary Cancer Tests"
            ]
        }
    ],
    "seo": {
        "meta_title": "Progenity, Inc. | Advanced Genetic Testing Solutions",
        "meta_description": "Explore Progenity, Inc., a leader in molecular diagnostics and genetic testing. Discover innovative solutions for prenatal testing and hereditary conditions.",
        "keywords": [
            "Progenity",
            "Genetic Testing",
            "Prenatal Testing",
            "Molecular Diagnostics",
            "Healthcare Innovation"
        ]
    },
    "faq": [
        {
            "question": "What type of tests does Progenity offer?",
            "answer": "Progenity offers genetic tests, including non-invasive prenatal testing and tests for gastrointestinal and hereditary cancers."
        },
        {
            "question": "Who is the CEO of Progenity?",
            "answer": "Harry Stylli is the CEO of Progenity, Inc."
        },
        {
            "question": "Where is Progenity headquartered?",
            "answer": "Progenity is headquartered in San Diego, California, USA."
        },
        {
            "question": "What is the Inherit test?",
            "answer": "The Inherit test is Progenity's flagship non-invasive prenatal test designed to assess the risk of genetic disorders."
        },
        {
            "question": "When was Progenity founded?",
            "answer": "Progenity was founded in 2010."
        }
    ],
    "competitors": [
        "NTRA",
        "ILMN",
        "GHDX",
        "PACB"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "VRTX",
        "BMY"
    ]
}